Allurion Technologies Holdings Inc. has released its financial results for the first quarter of 2025. The company reported total revenue of $5.6 million for the quarter ended March 31, 2025, compared to $9.4 million in the same period of 2024. Operating expenses for the quarter were $11.4 million, a significant reduction from $18.3 million in the previous year. The adjusted operating expenses were $10.1 million, excluding $1.4 million of one-time costs related to financings. The company reported a net operating loss of $7.3 million, a 36% decrease compared to the prior year, with an adjusted net operating loss of $5.9 million, marking a 48% reduction compared to the previous year. The gross margin improved to 75% from 73% in the prior year. Allurion has maintained its 2025 revenue guidance of approximately $30 million, while projecting a reduction in operating expenses by approximately 50% compared to 2024. In addition, the company has made progress on its business operations, having presented topline AUDACITY results to the FDA, completed a Pre-PMA meeting, and is on track to submit the final module of PMA by the end of June. Furthermore, Allurion has selected sites and drafted a protocol for a prospective trial on the combination of the Allurion Program with low-dose GLP-1 medications.